4 Results for "

anti-NSCLC

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "anti-NSCLC" in MCE Product Catalog:

Cat. No.: HY-173218
Target:  

EGFR

Research Areas:  

Cancer

anti-NSCLC agent-1 (compound 8dc) is an inhibitor of tyrosine kinase inhibitors (TKIs) with IC50 values of 0.05 and 0.09 μM in A549 and NCI-H441 cells. anti-NSCLC agent-1 shows anti-NSCLC activities in colony formation, migration, and invasion .
loading...
    loading...
Cat. No.: HY-182052
CAS No.: 3063042-21-4
Synonyms: anti-NSCLC agent-2
Ferroptosis inducer-16 (anti-NSCLC agent-2) is a nitric oxide (NO) donor and a ferroptosis inducer. Ferroptosis inducer-16 inhibits DNA synthesis and colony formation. Ferroptosis inducer-16 disrupts lysosomal integrity by releasing NO, triggers iron overload and oxidative stress, downregulates the SLC7A11-GPX4 axis, depletes GSH, and accumulates lipid peroxides. Ferroptosis inducer-16 inhibits tumor growth in an OVCAR8/ADR xenograft mouse model without obvious toxicity, and can be used in the study of non-small cell lung cancer and drug-resistant ovarian cancer .
loading...
    loading...
Cat. No.: HY-161388
Target:  

Ferroptosis Mitophagy

Research Areas:  

Cancer

NSCLC-IN-1 (Compound A10-2) induces mitophagy and ferroptosis through targeting transmembrane BAX inhibitor motif containing 6 (TMBIM6). NSCLC-IN-1 induces mitochondrial Ca 2+ imbalance, leading to mitochondrial damage. NSCLC-IN-1 reduces intracellular glutathione (GSH), increases the accumulation of lipid peroxides (LPO) and malondialdehyde (MDA) content. NSCLC-IN-1 is a potent anti-NSCLC agent .
loading...
    loading...
Cat. No.: HY-180853
Research Areas:  

Cancer

PI3K/Akt/mTOR-IN-6 (Compound JW4) is an orally active PI3K/Akt/mTOR pathway inhibitor. PI3K/Akt/mTOR-IN-6 induces Apoptosis in cells via the mitochondrial pathway. PI3K/Akt/mTOR-IN-6 shows potent anti-NSCLC activity .
loading...
    loading...